By Erika Wu, Business Development Representative, LSN
From the early days of his career, Dr. Chris Kent, President & CEO of ODS Medical, knew he wanted to push the limits of brain cancer tumor detection with Artificial Intelligence (AI). ODS Medical is looking to launch their first pivotal clinical trial by mid-2022. Chris is a former RESI AI panelist. Hear what he and the team have been working on this year and register now for RESI AI (September 16-17) and tell your story at the Innovator’s Pitch Challenge!
Leave a Reply